Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, June 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 123 articles: HTML format

Single Articles

1. LI Y, Ye F, Liu G, Cheng L, et al
   Nano-armed bcg delivers Cu-Fe MOF to trigger dual cell death in bladder cancer.
   J Nanobiotechnology. 2026 May 29. doi: 10.1186/s12951-026-04590.
   PubMed    
   Abstract available
   
   

2. JUNG M, Park S, Jang I, Han D, et al
   Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer.
   Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-55438.
   PubMed    
   Abstract available
   
   

3. ZHENG H, Tian Y, Cai Z, Huang G, et al
   CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation.
   Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-48969.
   PubMed    
   Abstract available
   
   

4. GONTERO P, Perry R, Bridge D, Delattre DD, et al
   Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.
   Eur Urol Oncol. 2026 May 29:S2588-9311(26)00134.
   PubMed    
   Abstract available
   
   

5. NECCHI A, Brembilla G, Whiting K, Arita Y, et al
   AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.
   Eur Urol Oncol. 2026 May 29:S2588-9311(26)00133.
   PubMed    
   Abstract available
   
   

6. PALERU G, Singathala GS, Kural S, Kumar L, et al
   Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis.
   Urol Oncol. 2026;44:70-81.
   PubMed    
   Abstract available
   
   

7. ZHANG XW, Schlack K, Hartmann A, Steiner T, et al
   Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.
   Oncol Res Treat. 2026 May 29:1-8. doi: 10.1159/000552743.
   PubMed    
   Abstract available
   
   

8. ZHAO L, Chen HM, Li YT, Zhang T, et al
   Comparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis.
   J Robot Surg. 2026;20:552.
   PubMed    
   Abstract available
   
   

9. NASUTION RFG, Warli SM, Prapiska FF
   Prognostic significance of pretreatment hydronephrosis in radiotherapy-based bladder-preserving strategies for muscle-invasive bladder cancer: a systematic review and meta-analysis.
   Arch Ital Urol Androl. 2026 May 29:14945. doi: 10.4081/aiua.2026.14945.
   PubMed    
   Abstract available
   
   

10. TANG C, Liu Y, Wang TL, Ma J, et al
    Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.
    Hum Mutat. 2026;2026:2797474.
    PubMed    
    Abstract available
    
    

11. LI C, Fang R, Wang J, Wang Y, et al
    Urinary DNA methylation biomarkers for bladder cancer diagnosis: a single center case-control study.
    Front Oncol. 2026;16:1812094.
    PubMed    
    Abstract available
    
    

12. SAYGIN H, Bolat S, Kablan D, Yavuz H, et al
    Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.
    Adv Urol. 2026;2026:6524384.
    PubMed    
    Abstract available
    
    

13. 
    Correction to "Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence".
    Adv Urol. 2026;2026:9810919.
    PubMed    
    Abstract available
    
    

14. CHEN IA, Luo HL, Chu CH, Yu CC, et al
    Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease.
    J Robot Surg. 2026;20:549.
    PubMed    
    Abstract available
    
    

15. WEI W, Xiao X, Ren C, Zhang H, et al
    Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.
    Cell Death Discov. 2026 May 28. doi: 10.1038/s41420-026-03182.
    PubMed    
    Abstract available
    
    

16. ZHAO H, Liao J, Wing Sze HV, Liu K, et al
    EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.
    Eur Urol Oncol. 2026 May 28:S2588-9311(26)00137.
    PubMed    
    Abstract available
    
    

17. WANG M, Chen J, Wang C, He Y, et al
    Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review.
    Front Oncol. 2026;16:1745178.
    PubMed    
    Abstract available
    
    

18. COSKUN A, Sahin AB, Kabul S, Dagtekin ME, et al
    Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancer.
    Oncol Lett. 2026;32:299.
    PubMed    
    Abstract available
    
    

19. ZHAO X, Xu X
    ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway.
    Open Med (Wars). 2026;21:20261422.
    PubMed    
    Abstract available
    
    

20. CHANG Y, Sun N, Liu Y, Jin Z, et al
    Lnc00892 enhances cisplatin sensitivity by inducing apoptosis through the BTAF1/MDM2/STAT5B/XIAP axis in bladder cancer cells.
    Biol Direct. 2026 May 27. doi: 10.1186/s13062-026-00842.
    PubMed    
    Abstract available
    
    

21. YIM W, Kang H, Kang BH, McGinnis ME, et al
    Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
    Nat Nanotechnol. 2026 May 27. doi: 10.1038/s41565-026-02172.
    PubMed    
    Abstract available
    
    

22. HONG X, Hong T, Liu X, Yao P, et al
    UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer.
    Cancer Sci. 2026 May 27. doi: 10.1111/cas.70430.
    PubMed    
    Abstract available
    
    

23. ZHANG N, Liang H, Wang L, Yang T, et al
    [Investigating prognostic factors for T1 stage high-grade bladder cancer and developing a multi-marker risk prediction model using immunohistochemistry].
    Zhonghua Wai Ke Za Zhi. 2026;64:768-777.
    PubMed    
    Abstract available
    
    

24. ZHONG WL, Zheng HR, Lin TX
    [Liquid biopsy empowers precision medicine across the full course of bladder cancer].
    Zhonghua Wai Ke Za Zhi. 2026;64:695-700.
    PubMed    
    Abstract available
    
    

25. HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
    Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In p
    Eur Urol Focus. 2026 May 27:S2405-4569(26)00088.
    PubMed    
    
    
    

26. LIU T, Zhu C, Yan Z
    Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. h
    Eur Urol Focus. 2026 May 27:S2405-4569(26)00087.
    PubMed    
    
    
    

27. MAMTANI R, Squires P, Mojebi A, Hale B, et al
    Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.
    Urol Oncol. 2026 May 27:S1078-1439(26)00495.
    PubMed    
    
    
    

28. MA M, Wu H, Zhu D, Sun P, et al
    The Mechanistic Role of the lncRNA AC016876.2/miR-133a-3p/SPAG5 Axis in Regulating Autophagy and Malignant Behavior in Bladder Cancer Cells.
    Tohoku J Exp Med. 2026 May 28. doi: 10.1620/tjem.2026.
    PubMed    
    
    
    

29. RAHMAN SN, Keervani K, Zhao X, Perry CJ, et al
    Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.
    Front Oncol. 2026;16:1807817.
    PubMed    
    Abstract available
    
    

30. HUANG Z, Wang T, Xia W, Li Q, et al
    [Retracted]Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells.
    Exp Ther Med. 2026;32:186.
    PubMed    
    Abstract available
    
    

31. SUN R, Li Y, Zuo L, Tao J, et al
    [Myricetin inhibits proliferation and migration of bladder cancer cells by inhibiting HSP90AA1-mediated AKT phosphorylation].
    Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1039-1052.
    PubMed    
    Abstract available
    
    

32. GODLEWSKI D, Aebisher D, Bartusik-Aebisher D, Dynarowicz K, et al
    Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.
    Life (Basel). 2026;16:828.
    PubMed    
    Abstract available
    
    

33. SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
    Systems Biology and Multi-Omics Determinants of Response to Bladder-Preserving Trimodality Therapy in Muscle-Invasive Bladder Cancer.
    Life (Basel). 2026;16:826.
    PubMed    
    Abstract available
    
    

34. KARAKAYALI A, Seyyar M, Sanci PC, Sahin E, et al
    Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.
    Medicina (Kaunas). 2026;62:992.
    PubMed    
    Abstract available
    
    

35. KIM KH, Kang BJ, Lee CH, Kim S, et al
    Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Gemcitabine in Treatment-Naive Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis.
    J Clin Med. 2026;15:3890.
    PubMed    
    Abstract available
    
    

36. KIM SH, Gudlavalleti H, Lerner SP
    Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
    J Clin Med. 2026;15:3830.
    PubMed    
    Abstract available
    
    

37. UN S, Aydin VK, Kurt O, Lengerova G, et al
    Time-Dependent Effects of Cisplatin on Autophagy Gene Expression in Bladder Cancer Cells.
    Biomedicines. 2026;14:1006.
    PubMed    
    Abstract available
    
    

38. LI W, Liu D, Yin Q, Geng Y, et al
    Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.
    Curr Issues Mol Biol. 2026;48:489.
    PubMed    
    Abstract available
    
    

39. NEWMAN A, Hansel S, Gerrard G, Orton L, et al
    Real-World Evaluation of Uromonitor((R)) for Bladder Cancer Detection and Surveillance.
    Cancers (Basel). 2026;18:1650.
    PubMed    
    Abstract available
    
    

40. MOHAMED NE, Berry DL, McReynolds J, Korn T, et al
    Development and Evaluation of the Personal Patient Profile-Bladder Cancer (P3-BC): A Web-Based Decision Support System for Patients Considering Cystectomy and Urinary Diversion.
    Cancers (Basel). 2026;18:1501.
    PubMed    
    Abstract available
    
    

41. ZHENG L, Wang J, Han S, Zhong L, et al
    Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
    J Exp Clin Cancer Res. 2026;45:128.
    PubMed    
    
    
    

42. RAMMANT E, Fox L, De Padova S, Liedberg F, et al
    Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.
    Eur Urol Oncol. 2026 May 26:S2588-9311(26)00125.
    PubMed    
    Abstract available
    
    

43. KAYAR K, Kayar R, Ozdemir BB, Karabay E, et al
    Urinary pH and oncologic outcomes after bacillus calmette-guerin in non-muscle invasive bladder cancer: a retrospective cohort study.
    Actas Urol Esp (Engl Ed). 2026 May 25:501995. doi: 10.1016/j.acuroe.2026.501995.
    PubMed    
    Abstract available
    
    

44. CARLSEN B, Klingen TA, Andreassen BK, Beisland C, et al
    Tumor cell invasion in blood vessels but not lymphatic vessels in TURBT predicts poor prognosis in bladder cancer.
    Urol Oncol. 2026;44:26-35.
    PubMed    
    Abstract available
    
    

45. CHEN J, Ding Z, Lai S, Gan Z, et al
    Nanoparticles-mediated dual metabolic-immunological intervention reverses immunosuppression in muscle invasive bladder cancer.
    Biomaterials. 2026;335:124335.
    PubMed    
    Abstract available
    
    

46. MOFID B, Jafari A, Simforoosh N, Basiri A, et al
    Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.
    BMC Urol. 2026 May 25. doi: 10.1186/s12894-026-02187.
    PubMed    
    Abstract available
    
    

47. AIZEZI X, Silafu B, Shi H, Huang J, et al
    Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer.
    Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05304.
    PubMed    
    Abstract available
    
    

48. OZALP FR, Ellez HI, Arslan AM, Demirciler E, et al
    Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer.
    Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05310.
    PubMed    
    Abstract available
    
    

49. CAMPO-PEREZ V, Guallar-Garrido S, Cabrera-Rubio R, Herrero-Abadia P, et al
    Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.
    NPJ Biofilms Microbiomes. 2026 May 25. doi: 10.1038/s41522-026-01002.
    PubMed    
    Abstract available
    
    

50. ZHU C, Lu J, Zhu B, Liu B, et al
    ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer.
    Front Immunol. 2026;17:1743064.
    PubMed    
    Abstract available
    
    

51. XU Y, Zhao C, Fu S, Wu Y, et al
    Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.
    Mater Today Bio. 2026;38:103222.
    PubMed    
    Abstract available
    
    

52. HU K, Luo L, Li P, Wang X, et al
    Fibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer.
    Cytojournal. 2026;23:25.
    PubMed    
    Abstract available
    
    

53. CHEN L, Hang G, Wen Q, Ren L, et al
    Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.
    Front Oncol. 2026;16:1803259.
    PubMed    
    Abstract available
    
    

54. LI Z, Zhong H, Baptista-Hon D, Qiu J, et al
    JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study.
    Precis Clin Med. 2026;9:pbag012.
    PubMed    
    Abstract available
    
    

55. HAYASHI J, Sugimoto K, Kochi S, Toake M, et al
    [A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].
    Gan To Kagaku Ryoho. 2026;53:307-309.
    PubMed    
    Abstract available
    
    

56. SHORE ND, Powles TB, Bedke J, Galsky MD, et al
    Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
    Future Oncol. 2026 May 24:1-13. doi: 10.1080/14796694.2026.2671256.
    PubMed    
    
    
    

57. WEN J, Wei L, Huang J, Zhou L, et al
    Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer.
    BMC Biotechnol. 2026 May 23. doi: 10.1186/s12896-026-01170.
    PubMed    
    Abstract available
    
    

58. DUCCI G, Ciufolini G, Campioni G, Pasquale V, et al
    FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.
    Commun Biol. 2026 May 23. doi: 10.1038/s42003-026-10356.
    PubMed    
    Abstract available
    
    

59. ELAVARASU SM, Asheem I, M N, S UK, et al
    Transcriptomic insights into epigenetic and immunomodulatory roles of nuclear histone genes in bladder cancer: A bioinformatics approach.
    Adv Protein Chem Struct Biol. 2026;152:77-101.
    PubMed    
    Abstract available
    
    

60. KOBYLKA P, Murias M, Bakun P, Goslinski T, et al
    Cellular responses to morpholinated curcumin derivatives in human muscle-invasive bladder cancer cells.
    Toxicol In Vitro. 2026;115:106251.
    PubMed    
    Abstract available
    
    

61. SUN Z, Liu J, Fang Y, Ma L, et al
    Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy.
    ACS Nano. 2026 May 23. doi: 10.1021/acsnano.6c00407.
    PubMed    
    Abstract available
    
    

62. WANG M, Jia K, Wang Y, Yuan D, et al
    The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study.
    Medicine (Baltimore). 2026;105:e48966.
    PubMed    
    Abstract available
    
    

63. PRADHAN B, Mishra P, Dash P, Niharika, et al
    Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions.
    Urol Oncol. 2026 May 22:S1078-1439(26)00498.
    PubMed    
    Abstract available
    
    

64. WANG S, Tang Y, Xu Y, Wang Y, et al
    Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer.
    Anal Chem. 2026 May 22. doi: 10.1021/acs.analchem.6c00738.
    PubMed    
    Abstract available
    
    

65. ZHANG M, Liu H, Zhang Y, Zhu Z, et al
    HIV-related bladder cancer: A ten-year experience.
    Int J STD AIDS. 2026 May 22:9564624261449133. doi: 10.1177/09564624261449133.
    PubMed    
    Abstract available
    
    

66. MIYAKE M, Minegishi T, Aikawa T, Fukasawa T, et al
    Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery.
    Cancer Treat Res Commun. 2026;47:101241.
    PubMed    
    Abstract available
    
    

67. MUSANGILE FY, Matsuzaki I, Nishikawa T, Kojima F, et al
    Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights.
    Pathol Res Pract. 2026;284:156517.
    PubMed    
    Abstract available
    
    

68. BONNI S, Ramnath NWM, Selten K, Moza A, et al
    Bacillus Calmette-Guerin-Related Mycotic Pseudoaneurysm in the Aortic Arch: Clinical and Operative Challenges.
    Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag120.
    PubMed    
    Abstract available
    
    

69. NIWA K, Iinuma K, Nakano M, Tomioka M, et al
    Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
    Int J Clin Oncol. 2026;31:1008-1016.
    PubMed    
    Abstract available
    
    

70. MORRIS G, Vlachostergios PJ, Rai MP, Scherr D, et al
    19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.
    Cancer Genet. 2026;304-305:51-57.
    PubMed    
    Abstract available
    
    

71. JAN HC, Su YC, Huang SK, Wang CA, et al
    HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma.
    Cancer Treat Res Commun. 2026;47:101148.
    PubMed    
    Abstract available
    
    

72. QIN X, Zheng B, Liu D, Quan X, et al
    A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.
    J Nanobiotechnology. 2026;24:502.
    PubMed    
    Abstract available
    
    

73. CHOI SH, Kim JK, Kim SH, Ryu MO, et al
    Recurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma.
    Am J Vet Res. 2026;87:ajvr.
    PubMed    
    Abstract available
    
    

74. WANG Y, An S, Min Y
    Crocin-coated zinc-alginate-PEG nanocomposite induces ROS-mediated apoptosis via PI3K/Akt/mTOR suppression in bladder cancer cells.
    3 Biotech. 2026;16:248.
    PubMed    
    Abstract available
    
    

75. YILMAZ B, Ataman M, Tuna A
    Detection of microplastics in bladder wash fluid obtained after cystoscopy in patients diagnosed with bladder cancer.
    Front Public Health. 2026;14:1812477.
    PubMed    
    Abstract available
    
    

76. HE Y, Fang Z, Zhang J, Wei Q, et al
    Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.
    Theranostics. 2026;16:6827-6842.
    PubMed    
    Abstract available
    
    

77. BELLMUNT J, Xie Y, Juanpere N, Munoz MG, et al
    Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.
    Theranostics. 2026;16:6892-6910.
    PubMed    
    Abstract available
    
    

78. LIU J, Li B, Hou R, Sun J, et al
    A five-gene mitochondria-associated prognostic signature for bladder cancer.
    Int J Clin Exp Pathol. 2026;19:192-208.
    PubMed    
    Abstract available
    
    

79. YUAN H, Wang T, Peng P, Xu Z, et al
    Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1].
    Clin Genitourin Cancer. 2026 Jun 4:102584. doi: 10.1016/j.clgc.2026.102584.
    PubMed    
    
    
    

80. PALMBOS P, Kelleher A, Henderson M, Broses L, et al
    TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.
    Res Sq [Preprint]. 2026 May 20:rs.3.rs-9214925. doi: 10.21203/rs.3.rs-9214925.
    PubMed    
    Abstract available
    
    

81. YIM K, Vergara M, Lee J, Reardon B, et al
    Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
    bioRxiv [Preprint]. 2026 May 18:2026.05.10.724123.
    PubMed    
    Abstract available
    
    

82. FINI MS, Alley JR, Vensko SP, Karthikeyan D, et al
    Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.
    bioRxiv [Preprint]. 2026 May 27:2026.05.20.726664.
    PubMed    
    Abstract available
    
    

83. HUANG Z, Yan Y, Wang X, Li H, et al
    Tumor-derived WNT7A reprograms pulmonary fibroblasts to remodel the metastatic niche and promote bladder cancer lung metastasis.
    Exp Mol Med. 2026 Jun 3. doi: 10.1038/s12276-026-01735.
    PubMed    
    Abstract available
    
    

84. MACDONALD LP, Kypriotakis G, Karam-Hage M, Minnix JA, et al
    Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.
    Eur Urol Oncol. 2026 Jun 3:S2588-9311(26)00131-8. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available
    
    

85. DIAZ GM, Isali I, Davis L, Wang B, et al
    Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
    Clin Genitourin Cancer. 2026 May 6:102578. doi: 10.1016/j.clgc.2026.102578.
    PubMed    
    Abstract available
    
    

86. MUNK L, Kumarasegaram V, Hyldgaard JM, Jensen JB, et al
    Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.
    Urol Oncol. 2026;44:101-107.
    PubMed    
    Abstract available
    
    

87. ZHANG XJ, Yu HY, Cai YJ, Ke M, et al
    Retraction: Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
    Oncotarget. 2026;17:193-194.
    PubMed    
    
    
    

88. HUANG J, Luo H, Du C, Zhai Q, et al
    Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.
    Clin Nephrol. 2026 Jun 3. doi: 10.5414/CN111972.
    PubMed    
    Abstract available
    
    

89. LIU Z, Yao Z, Hou Y, Liu Z, et al
    LGALS1-CD276 Paracrine axis between tumor and endothelial cells promotes tumor angiogenesis and progression in bladder cancer.
    Cell Death Differ. 2026 Jun 2. doi: 10.1038/s41418-026-01777.
    PubMed    
    Abstract available
    
    

90. PINTON P, Kawano H, Patschan O, Ravi A, et al
    A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer.
    Sci Rep. 2026 Jun 2. doi: 10.1038/s41598-026-55917.
    PubMed    
    Abstract available
    
    

91. LUO Y, Ma J, Wang C, Xiong W, et al
    ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer.
    Cell Signal. 2026 Jun 1:112633. doi: 10.1016/j.cellsig.2026.112633.
    PubMed    
    Abstract available
    
    

92. NARAYAN A, Leibrandt RC, Lee JS, Dall'Era MA, et al
    A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
    Nanomedicine (Lond). 2026 Jun 1:1-6. doi: 10.1080/17435889.2026.2674162.
    PubMed    
    Abstract available
    
    

93. NIKOLAUS Y
    p40-positive metastatic urothelial carcinoma mimicking primary pulmonary squamous cell carcinoma on limited lung biopsy.
    BMJ Case Rep. 2026;19:e272914.
    PubMed    
    Abstract available
    
    

94. YANG H, Zhou C, Zhou Z, Zhang F, et al
    YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer.
    Int Immunopharmacol. 2026;184:116911.
    PubMed    
    Abstract available
    
    

95. KOHLER J, Buck L, Schliesser P, Weische O, et al
    Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.
    Urol Oncol. 2026;44:92-100.
    PubMed    
    Abstract available
    
    

96. FU L, Huang B, Shi L, Geng Y, et al
    DS-MTNet: A dual-stream multi-task network for histopathology localization and histologic risk stratification from small biopsy specimens of bladder cancer.
    Comput Methods Programs Biomed. 2026;284:109464.
    PubMed    
    Abstract available
    
    

97. ZHANG W, Wu H, Wang L, Xu H, et al
    Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    JAMA Netw Open. 2026;9:e2614764.
    PubMed    
    Abstract available
    
    

98. ZHANG Y, Li R, Shi H, Zhao A, et al
    ASO Author Reflections: Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
    Ann Surg Oncol. 2026 Jun 1. doi: 10.1245/s10434-026-19845.
    PubMed    
    
    
    

99. CHEN L, Cao X, Lu Z, Liu L, et al
    Artificial intelligence-assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma.
    Cancer Cytopathol. 2026;134:e70120.
    PubMed    
    Abstract available
    
    

100. JIAO B, Xu Y, Wang X, Zhang H, et al
     Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer.
     ACS Appl Bio Mater. 2026 Jun 1. doi: 10.1021/acsabm.6c00552.
     PubMed    
     Abstract available
     
     

101. BOYNE A, Anderson RC, Liu D, Varghese B, et al
     Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.
     Bladder Cancer. 2026;12:23523735261455396.
     PubMed    
     Abstract available
     
     

102. BOLT MJ, Oceguera J, Tostado AR, Candler CD, et al
     A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer.
     Pharmacol Res Nat Prod. 2025;7:100236.
     PubMed    
     Abstract available
     
     

103. SELVARAJU A, Dwivedi DK, Patbamniya NK, Kumar M, et al
     Multiparametric MRI Radiomics for the Prediction of Histologic Grade in Bladder Cancer.
     Indian J Surg Oncol. 2026;17:1057-1064.
     PubMed    
     Abstract available
     
     

104. FERNANDES C, Brito C, Ferreira C, Botelho F, et al
     Ensuring Timely Detection of Bladder Cancer: The Role of a Screening for Haematuria Consultations.
     Indian J Surg Oncol. 2026;17:964-969.
     PubMed    
     Abstract available
     
     

105. YANG J, You Z, Mo H, Pu J, et al
     Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data.
     Front Immunol. 2026;17:1797389.
     PubMed    
     Abstract available
     
     

106. HANSEN MS, Dyrskjot L, Heide-Jorgensen U, Jensen JB, et al
     Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.
     J Intern Med. 2026 Jun 1. doi: 10.1111/joim.70115.
     PubMed    
     Abstract available
     
     

107. ICHIYAMA T, Narita T, Sekine Y, Shinohara M, et al
     Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.
     Jpn J Clin Oncol. 2026 May 31:hyag087. doi: 10.1093.
     PubMed    
     Abstract available
     
     

108. GUTTI JR, Clarke DM, Saba C, Nagata K, et al
     Incorporating Hypofractionated Radiotherapy Improves Management of Canine Urothelial Carcinoma: A Retrospective Study.
     Vet Radiol Ultrasound. 2026;67:e70196.
     PubMed    
     Abstract available
     
     

109. ABOU CHAKRA M, Duquesne I, O'Donnell MA
     Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
     Front Biosci (Landmark Ed). 2026;31:47606.
     PubMed    
     Abstract available
     
     

110. GUPTA A, Chandra S, Verma T, Gupta A, et al
     The Paris System for Urine Cytology: Prospective Assessment of Reproducibility, Diagnostic Accuracy, and Malignancy Risk.
     Diagn Cytopathol. 2026;54:506-518.
     PubMed    
     Abstract available
     
     

111. MACH KE, Kornberg Z, Shkolyar E, Long J, et al
     Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.
     J Clin Invest. 2026;136:e203094.
     PubMed    
     Abstract available
     
     

112. KLATTE T, Hofbauer SL, Ebert J, Ecke TH, et al
     Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.
     Anticancer Res. 2026;46:3333-3342.
     PubMed    
     Abstract available
     
     

113. SABBADINI P, Paganoni E, Galeasso L, Depetris I, et al
     Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review.
     Anticancer Res. 2026;46:3517-3522.
     PubMed    
     Abstract available
     
     

114. ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
     Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
     BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
     PubMed    
     Abstract available
     
     

115. MURRAY BO, Gao J, Pasquina-Lemonche L, Swarbrick K, et al
     An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.
     Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03476.
     PubMed    
     Abstract available
     
     

116. ROELS J, Ghaedi H, Kancherla J, Yang Y, et al
     The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
     Cancer Res. 2026;86:2592-2605.
     PubMed    
     Abstract available
     
     

117. MAIORANO BA, Dizman N, Necchi A
     Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma.
     Eur Urol. 2026;89:479-482.
     PubMed    
     Abstract available
     
     

118. NISHIMURA N, Miyake M, Iwao T, Oda Y, et al
     Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
     Int J Urol. 2026;33:e70526.
     PubMed    
     Abstract available
     
     

119. CATHOMAS R, Petrausch U, Hayoz S, Spahn M, et al
     Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
     J Clin Oncol. 2026 May 29:101200JCO2600845. doi: 10.1200/JCO-26-00845.
     PubMed    
     Abstract available
     
     

120. NECCHI A, de Jong JJ, Maiorano BA, Proudfoot JA, et al
     Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
     J Clin Oncol. 2026 May 31:JCO2600142. doi: 10.1200/JCO-26-00142.
     PubMed    
     Abstract available
     
     

121. PRASAD S
     Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial.
     J Urol. 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
     PubMed    
     
     
     

122. CHEN C, Liu X, Xu A, Jiang N, et al
     Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
     BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
     PubMed    
     Abstract available
     
     

123. WU Q, Lu P, Zhang X, Qing X, et al
     Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
     BMC Cancer. 2026;26:680.
     PubMed    
     Abstract available